{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:31:31Z","timestamp":1785796291288,"version":"3.56.0"},"reference-count":311,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":1844,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T00:00:00Z","timestamp":1607126400000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Research about heart failure (HF) has made major progress in the last years. We give here an update on the most recent findings. Landmark trials have established new treatments for HF with reduced ejection fraction. Sacubitril\/valsartan was superior to enalapril in PARADIGM-HF trial, and its initiation during hospitalization for acute HF or early after discharge can now be considered. More recently, new therapeutic pathways have been developed. In the DAPA-HF and EMPEROR-Reduced trials, dapagliflozin and empagliflozin reduced the risk of the primary composite endpoint, compared with placebo [hazard ratio (HR) 0.74; 95% confidence interval (CI) 0.65\u20130.85; P &amp;lt; 0.001 and HR 0.75; 95% CI 0.65\u20130.86; P &amp;lt; 0.001, respectively]. Second, vericiguat, an oral soluble guanylate cyclase stimulator, reduced the composite endpoint of cardiovascular death or HF hospitalization vs. placebo (HR 0.90; 95% CI 0.82\u20130.98; P = 0.02). On the other hand, both the diagnosis and treatment of HF with preserved ejection fraction, as well as management of advanced HF and acute HF, remain challenging. A better phenotyping of patients with HF would be helpful for prognostic stratification and treatment selection. Further aspects, such as the use of devices, treatment of arrhythmias, and percutaneous treatment of valvular heart disease in patients with HF, are also discussed and reviewed in this article.<\/jats:p>","DOI":"10.1002\/ehf2.13124","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T03:04:56Z","timestamp":1607137496000},"page":"3505-3530","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Heart Failure in the Last Year: Progress and Perspective"],"prefix":"10.1093","volume":"7","author":[{"given":"Daniela","family":"Tomasoni","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]},{"name":"Cardiology and Cardiac Catheterization Laboratory, Cardio-thoracic Department, Civil Hospitals , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Adamo","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]},{"name":"Cardiology and Cardiac Catheterization Laboratory, Cardio-thoracic Department, Civil Hospitals , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus S.","family":"Anker","sequence":"additional","affiliation":[{"name":"Division of Cardiology and Metabolism, Department of Cardiology (CVK), Charit\u00e9\u2013University Medicine Berlin , Berlin ,","place":["Germany"]},{"name":"Berlin Institute of Health Center for Regenerative Therapies (BCRT) , Berlin ,","place":["Germany"]},{"name":"German Centre for Cardiovascular Research (DZHK), partner site Berlin , Berlin ,","place":["Germany"]},{"name":"Department of Cardiology (CBF), Charit\u00e9\u2013University Medicine Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Pneumology, University of G\u00f6ttingen Medical Center , G\u00f6ttingen ,","place":["Germany"]},{"name":"German Centre for Cardiovascular Research (DZHK), partner site G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J. S.","family":"Coats","sequence":"additional","affiliation":[{"name":"Centre for Clinical and Basic Research, Department of Medical Sciences, IRCCS San Raffaele Pisana , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6691-8568","authenticated-orcid":false,"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]},{"name":"Cardiology and Cardiac Catheterization Laboratory, Cardio-thoracic Department, Civil Hospitals , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,5]]},"reference":[{"key":"2026012115024566600_ehf213124-bib-0001","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/ejhf.1577","article-title":"The economic burden of heart failure in Denmark from 1998 to 2016","volume":"21","author":"Bundgaard","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"Savarese","year":"2017","journal-title":"Card Fail Rev"},{"key":"2026012115024566600_ehf213124-bib-0003","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijcard.2013.12.028","article-title":"The annual global economic burden of heart failure","volume":"171","author":"Cook","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026012115024566600_ehf213124-bib-0004","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12872-018-0815-3","article-title":"Cost-of-illness studies in heart failure: a systematic review 2004\u20132016","volume":"18","author":"Lesyuk","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"2026012115024566600_ehf213124-bib-0005","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","article-title":"The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries","volume":"63","author":"Ambrosy","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026012115024566600_ehf213124-bib-0006","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ehf2.12363","article-title":"Assessing health-related quality of life in heart failure patients attending an outpatient clinic: a pragmatic approach","volume":"6","author":"Gallagher","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0007","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ehf2.12369","article-title":"Self-reported health and quality of life outcomes of heart failure patients in the aftermath of a national economic crisis: a cross-sectional study","volume":"6","author":"Ketilsdottir","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0008","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/HCR.0b013e31819a0266","article-title":"Quality of life in a diverse population of patients with heart failure: BASELINE FINDINGS FROM THE HEART FAILURE ADHERENCE AND RETENTION TRIAL (HART)","volume":"29","author":"de Leon","year":"2009","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"2026012115024566600_ehf213124-bib-0009","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(17)30196-1","article-title":"Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study","volume":"5","author":"Dokainish","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2026012115024566600_ehf213124-bib-0010","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ijcard.2015.04.235","article-title":"The patient perspective: quality of life in advanced heart failure with frequent hospitalisations","volume":"191","author":"Nieminen","year":"2015","journal-title":"Int J Cardiol"},{"key":"2026012115024566600_ehf213124-bib-0011","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/ejhf.1594","article-title":"Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis","volume":"21","author":"Jones","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0012","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ejhf.1227","article-title":"Heart failure with preserved ejection fraction in Asia","volume":"21","author":"Tromp","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0013","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/ejhf.1629","article-title":"Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012\u20132015","volume":"21","author":"Hao","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0014","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ejhf.1768","article-title":"The Heart Failure Association Atlas: rationale, objectives, and methods","volume":"22","author":"Seferovi\u0107","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0015","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ejhf.822","article-title":"Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland","volume":"19","author":"Mamas","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0016","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ejhf.1609","article-title":"Heart failure in Norway, 2000\u20132014: analysing incident, total and readmission rates using data from the Cardiovascular Disease in Norway (CVDNOR) Project","volume":"22","author":"Sulo","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0017","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/ejhf.1585","article-title":"Heart failure around the world","volume":"21","author":"Tromp","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0018","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ejhf.1347","article-title":"Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia","volume":"21","author":"Dewan","year":"2019","journal-title":"Europe and the Americas Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0019","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ejhf.1358","article-title":"Impact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIAN-HF registry","volume":"21","author":"Chandramouli","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0020","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/ejhf.1350","article-title":"Risk factors for incident heart failure in age- and sex-specific strata: a population-based cohort using linked electronic health records","volume":"21","author":"Uijl","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0021","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ejhf.1644","article-title":"Selenium and outcome in heart failure","volume":"22","author":"Bomer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0022","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/ejhf.1210","article-title":"Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan","volume":"20","author":"Nagai","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0023","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ehf2.12494","article-title":"Strong muscles, weak heart: testosterone-induced cardiomyopathy","volume":"6","author":"Doleeb","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0024","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/ehf2.12360","article-title":"Circulating markers of collagen types I, III, and IV in patients with dilated cardiomyopathy: relationships with myocardial collagen expression","volume":"5","author":"Nagao","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0025","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ehf2.12420","article-title":"Genetic basis and outcome in a nationwide study of Finnish patients with hypertrophic cardiomyopathy","volume":"6","author":"J\u00e4\u00e4skel\u00e4inen","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0026","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ehf2.12240","article-title":"Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial","volume":"5","author":"Bocchi","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0027","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ejhf.1461","article-title":"Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovi\u0107","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0028","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/ejhf.1241","article-title":"The clinical outcome of LMNA missense mutations can be associated with the amount of mutated protein in the nuclear envelope","volume":"20","author":"Al-Saaidi","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0029","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/ejhf.1534","article-title":"Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report","volume":"21","author":"Elliott","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0030","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/ehf2.12267","article-title":"Genetic determinants of heart failure: facts and numbers","volume":"5","author":"Czepluch","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0031","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ejhf.1423","article-title":"High risk of heart failure associated with desmoglein-2 mutations compared to plakophilin-2 mutations in arrhythmogenic right ventricular cardiomyopathy\/dysplasia","volume":"21","author":"Hermida","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0032","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ejhf.1456","article-title":"Heart failure in arrhythmogenic cardiomyopathy: is phenotypic variability just a matter of genetics?","volume":"21","author":"Pilichou","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0033","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ehf2.12518","article-title":"Transthyretin cardiac amyloidosis: an update on diagnosis and treatment","volume":"6","author":"Yamamoto","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0034","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0035","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ehf2.12382","article-title":"Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy","volume":"6","author":"Shintani","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0036","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.111.069195","article-title":"Cardiac amyloidosis","volume":"126","author":"Quarta","year":"2012","journal-title":"Circulation"},{"key":"2026012115024566600_ehf213124-bib-0037","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/ejhf.899","article-title":"Inotropic myocardial reserve deficiency is the predominant feature of exercise haemodynamics in cardiac amyloidosis","volume":"19","author":"Clemmensen","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0038","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/ejhf.1285","article-title":"Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure","volume":"20","author":"Gagliardi","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0039","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ejhf.1531","article-title":"Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0040","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/ejhf.1493","article-title":"Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy","volume":"21","author":"Bauersachs","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0041","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/ejhf.1202","article-title":"Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study","volume":"20","author":"Iorio","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0042","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/ejhf.1073","article-title":"Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure","volume":"20","author":"Wolsk","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0043","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/ejhf.1236","article-title":"Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Crespo-Leiro","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0044","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ejhf.1404","article-title":"Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy","volume":"21","author":"Ambrosy","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.amjmed.2014.08.024","article-title":"Multimorbidity in heart failure: a community perspective","volume":"128","author":"Chamberlain","year":"2015","journal-title":"Am J Med"},{"key":"2026012115024566600_ehf213124-bib-0046","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/ejhf.1223","article-title":"Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry","volume":"20","author":"Cooper","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0047","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ejhf.1666","article-title":"Type 2 diabetes increases the long-term risk of heart failure and mortality in patients with atrial fibrillation","volume":"22","author":"Polovina","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0048","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ejhf.1146","article-title":"Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes","volume":"20","author":"Cosmi","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0049","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/ejhf.1201","article-title":"Microvascular complications in diabetes patients with heart failure and reduced ejection fraction-insights from the Beta-blocker Evaluation of Survival Trial","volume":"20","author":"Kristensen","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0050","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/jcsm.12515","article-title":"Chronic heart failure with diabetes mellitus is characterized by a severe skeletal muscle pathology","volume":"11","author":"Garnham","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026012115024566600_ehf213124-bib-0051","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/jcsm.12471","article-title":"Weight loss in heart failure is associated with increased mortality only in non-obese patients without diabetes","volume":"10","author":"Niedziela","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026012115024566600_ehf213124-bib-0052","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/ejhf.1541","article-title":"Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure","volume":"21","author":"Coiro","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0053","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/jcsm.12421","article-title":"Kidney cachexia or protein-energy wasting in chronic kidney disease: facts and numbers","volume":"10","author":"Koppe","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026012115024566600_ehf213124-bib-0054","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ejhf.964","article-title":"Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry","volume":"20","author":"Canepa","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0055","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ejhf.1100","article-title":"Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association","volume":"20","author":"Doehner","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0056","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ejhf.1334","article-title":"Prognostic value of baroreflex sensitivity in heart failure. A 2018 reappraisal","volume":"21","author":"Parati","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0057","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ejhf.1433","article-title":"Cardiorespiratory fitness, body mass index and heart failure incidence","volume":"21","author":"Kokkinos","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0058","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/ejhf.1569","article-title":"Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise","volume":"21","author":"Moliner","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0059","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/ejhf.1539","article-title":"Cancer and heart disease: associations and relations","volume":"21","author":"de Boer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0060","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/ejhf.1168","article-title":"Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial","volume":"20","author":"Banke","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0061","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ejhf.1376","article-title":"The role of irradiated heart and left ventricular volumes in heart failure occurrence after childhood cancer","volume":"21","author":"Mansouri","journal-title":"Eur J Heart Fail 201"},{"key":"2026012115024566600_ehf213124-bib-0062","doi-asserted-by":"crossref","first-page":"L24","DOI":"10.1093\/eurheartj\/suz241","article-title":"Cardiac cachexia","volume":"21","author":"Lena","year":"2019","journal-title":"Eur Heart J Suppl"},{"key":"2026012115024566600_ehf213124-bib-0063","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/SPC.0000000000000456","article-title":"Cardiac cachexia: the mandate to increase clinician awareness","volume":"13","author":"Lena","year":"2019","journal-title":"Curr Opin Support Palliat Care"},{"key":"2026012115024566600_ehf213124-bib-0064","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/jcsm.12265","article-title":"Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle","volume":"9","author":"Hulmi","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026012115024566600_ehf213124-bib-0065","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/jcsm.12483","article-title":"Sarcopenia: a time for action. An SCWD position paper","volume":"10","author":"Bauer","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026012115024566600_ehf213124-bib-0066","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ehf2.12388","article-title":"Muscle wasting and sarcopenia in heart failure: a brief overview of the current literature","volume":"5","author":"von Haehling","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0067","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/jcsm.12603","article-title":"Muscle wasting as an independent predictor of survival in patients with chronic heart failure","volume":"11","author":"von Haehling","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026012115024566600_ehf213124-bib-0068","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/ehf2.12387","article-title":"Skeletal muscle wasting in chronic heart failure","volume":"5","author":"Suzuki","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0069","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.3390\/ijms21186549","article-title":"Muscle wasting and sarcopenia in heart failure\u2013the current state of science","volume":"21","author":"Lena","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026012115024566600_ehf213124-bib-0070","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/ehf2.12389","article-title":"Metabolic disorders in heart failure and cancer","volume":"5","author":"Lena","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0071","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/jcsm.12495","article-title":"Effects of aerobic and inspiratory training on skeletal muscle microRNA-1 and downstream-associated pathways in patients with heart failure","volume":"11","author":"Antunes-Correa","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026012115024566600_ehf213124-bib-0072","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/ejhf.1611","article-title":"Heart Failure Association\/European Society of Cardiology position paper on frailty in patients with heart failure","volume":"21","author":"Vitale","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0073","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1926","article-title":"Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: the FRAGILE-HF cohort study","author":"Matsue","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0074","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2011","article-title":"Cachexia, muscle wasting, and frailty in cardiovascular disease","author":"Bielecka-Dabrowa","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0075","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jacc.2011.11.040","article-title":"Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction","volume":"59","author":"Ather","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026012115024566600_ehf213124-bib-0076","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/ejhf.1308","article-title":"The frailty syndrome and outcomes in the TOPCAT trial","volume":"20","author":"Sanders","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0077","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/ejhf.1112","article-title":"Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERA-HF study","volume":"20","author":"Sokoreli","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0078","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/jcsm.12411","article-title":"Sarcopenia and its association with falls and fractures in older adults: a systematic review and meta-analysis","volume":"10","author":"Yeung","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026012115024566600_ehf213124-bib-0079","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/jcsm.12477","article-title":"The Copenhagen Sarcopenia Study: lean mass, strength, power, and physical function in a Danish cohort aged 20\u201393 years","volume":"10","author":"Suetta","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026012115024566600_ehf213124-bib-0080","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/ehf2.12481","article-title":"Impact of sex, socio-economic status, and remoteness on therapy and survival in heart failure","volume":"6","author":"Gutman","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0081","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/ehf2.12307","article-title":"Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines","volume":"5","author":"Levinsson","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0082","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ehf2.12483","article-title":"Sex differences on peak oxygen uptake in heart failure","volume":"6","author":"Palau","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0083","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006539","article-title":"Sex-related differences in heart failure with preserved ejection fraction","volume":"12","author":"Dewan","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0084","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/ejhf.1252","article-title":"Cancer and heart failure\u2013more than meets the eye: common risk factors and co-morbidities","volume":"20","author":"Anker","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0085","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/ehf2.12386","article-title":"Modern-day cardio-oncology: a report from the \u2018Heart Failure and World Congress on Acute Heart Failure 2018\u2019","volume":"5","author":"Anker","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0086","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/ehf2.12551","article-title":"Recent advances in cardio-oncology: a report from the \u2018Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019\u2019","volume":"6","author":"Anker MS","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0087","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/ejhf.670","article-title":"Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non-small cell lung cancer: results of a prospective cardiovascular long-term study","volume":"18","author":"Anker","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0088","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ejhf.1165","article-title":"Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge","volume":"20","author":"Ameri","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0089","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ejhf.1049","article-title":"Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience","volume":"20","author":"Fornaro","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0090","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/ejhf.1292","article-title":"Activity and outcomes of a cardio-oncology service in the United Kingdom\u2013a five-year experience","volume":"20","author":"Pareek","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0091","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ehf2.12493","article-title":"Heart failure from cancer therapy: can we prevent it?","volume":"6","author":"Totzeck","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0092","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/ehf2.12277","article-title":"Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy","volume":"5","author":"Muehlberg","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0093","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115024566600_ehf213124-bib-0094","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ejhf.1610","article-title":"Myocardial dysfunction in long-term breast cancer survivors treated at ages 40\u201350\u2009years","volume":"22","author":"Jacobse","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0095","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/ejhf.1385","article-title":"Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients","volume":"21","author":"Keramida","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0096","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0097","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ejhf.1439","article-title":"The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity","volume":"21","author":"Russo","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0098","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ehf2.12278","article-title":"Performance of the MAGGIC heart failure risk score and its modification with the addition of discharge natriuretic peptides","volume":"5","author":"Sawano","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0099","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/ejhf.989","article-title":"Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison","volume":"20","author":"Agostoni","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0100","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/ejhf.1450","article-title":"Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score","volume":"21","author":"O'Connor","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0101","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ejhf.1628","article-title":"Improving risk prediction in heart failure using machine learning","volume":"22","author":"Adler","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0102","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ejhf.1131","article-title":"Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and\/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative","volume":"20","author":"Ferreira","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0103","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/ejhf.1162","article-title":"Interaction of systolic blood pressure and resting heart rate with clinical outcomes in takotsubo syndrome: insights from the International Takotsubo Registry","volume":"20","author":"B\u00f6hm","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0104","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012115024566600_ehf213124-bib-0105","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ejhf.1389","article-title":"Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction","volume":"21","author":"Sartipy","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0106","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ejhf.1494","article-title":"Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations","volume":"21","author":"Mueller","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0107","doi-asserted-by":"crossref","first-page":"329","DOI":"10.5603\/KP.2019.0051","article-title":"Novel biomarkers in heart failure and cardio-oncology","volume":"77","author":"Anker","year":"2019","journal-title":"Kardiol Pol"},{"key":"2026012115024566600_ehf213124-bib-0108","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/ejhf.1209","article-title":"Sex- specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population","volume":"20","author":"Suthahar","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0109","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/ejhf.988","article-title":"Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study","volume":"20","author":"Welsh","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0110","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ejhf.1381","article-title":"Prediction of incident heart failure by serum amino-terminal pro-B-type natriuretic peptide level in a community-based cohort","volume":"21","author":"Campbell","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0111","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ejhf.1019","article-title":"Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial","volume":"20","author":"Greene","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0112","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ejhf.1359","article-title":"The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes","volume":"21","author":"R\u00f8rth","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0113","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.1654","article-title":"Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-CHF study","volume":"22","author":"Ferreira","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0114","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/ejhf.1495","article-title":"Mid-regional pro-atrial natriuretic peptide for the early detection of non-acute heart failure","volume":"21","author":"Gohar","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0115","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ejhf.973","article-title":"Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial","volume":"20","author":"Vaduganathan","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0116","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/ejhf.1607","article-title":"Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial","volume":"21","author":"Rachwan","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0117","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/ejhf.1301","article-title":"Growth differentiation factor-15 is not modified by sacubitril\/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial","volume":"20","author":"Bouabdallaoui","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0118","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/ejhf.963","article-title":"Inflammation and cardio-renal interactions in heart failure: a potential role for interleukin-6","volume":"20","author":"Hanberg","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0119","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ejhf.1039","article-title":"Intramyocardial inflammation predicts adverse outcome in patients with cardiac AL amyloidosis","volume":"20","author":"Siegismund","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0120","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ejhf.1167","article-title":"Derangements in adrenergic-adipokine signalling establish a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction","volume":"20","author":"Packer","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0121","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ejhf.1320","article-title":"Treating oxidative stress in heart failure: past, present and future","volume":"21","author":"van der Pol","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0122","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/ejhf.1482","article-title":"The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study","volume":"21","author":"Markousis-Mavrogenis","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0123","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ejhf.1119","article-title":"Transcoronary concentration gradients of circulating microRNAs in heart failure","volume":"20","author":"De Rosa","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0124","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ejhf.950","article-title":"Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure","volume":"20","author":"van Boven","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0125","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ejhf.984","article-title":"Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patients","volume":"20","author":"Bay\u00e9s-Genis","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0126","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ejhf.961","article-title":"Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure","volume":"20","author":"Masson","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0127","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ejhf.1366","article-title":"Adrenomedullin in heart failure: pathophysiology and therapeutic application","volume":"21","author":"Voors","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0128","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ejhf.1342","article-title":"Effects of sacubitril\/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study","volume":"21","author":"Nougu\u00e9","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0129","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/ejhf.1409","article-title":"Trimethylamine N-oxide and risk of heart failure progression: marker or mediator of disease","volume":"21","author":"Chioncel","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ejhf.971","article-title":"Non-invasive assessment of left ventricular filling pressure","volume":"20","author":"Nagueh","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"2026012115024566600_ehf213124-bib-0132","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ejhf.928","article-title":"Left ventricular ejection time is an independent predictor of incident heart failure in a community-based cohort","volume":"20","author":"Biering-S\u00f8rensen","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0133","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/ejhf.1659","article-title":"Association between systolic ejection time and outcomes in heart failure by ejection fraction","volume":"22","author":"Patel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0134","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/ejhf.1606","article-title":"Left atrial structure and function and the risk of death or heart failure in atrial fibrillation","volume":"21","author":"Inciardi","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0135","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.1464","article-title":"Left atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fraction","volume":"21","author":"Reddy","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0136","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ejhf.1399","article-title":"Impaired left atrial strain predicts abnormal exercise haemodynamics in heart failure with preserved ejection fraction","volume":"21","author":"Telles","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0137","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ejhf.1677","article-title":"Mitral regurgitation, left atrial structural and functional remodelling and the effect on pulmonary haemodynamics","volume":"22","author":"Inciardi","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0138","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ejhf.1406","article-title":"Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology","volume":"21","author":"de Boer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0139","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/ejhf.1617","article-title":"Myocardial adipose deposition and the development of heart failure with preserved ejection fraction","volume":"22","author":"Wu","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0140","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/ejhf.1283","article-title":"Epicardial fat in heart failure patients with mid-range and preserved ejection fraction","volume":"20","author":"van Woerden","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0141","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/ejhf.1380","article-title":"Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study","volume":"21","author":"Ferreira","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0142","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ejhf.1364","article-title":"Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years","volume":"21","author":"Paolillo","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0143","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ejhf.1595","article-title":"Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction","volume":"21","author":"Rovai","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0144","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ejhf.860","article-title":"Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC\/ERS guidelines and insights for future changes","volume":"20","author":"Palazzini","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0145","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ejhf.1322","article-title":"Haemodynamic mechanisms and long-term prognostic impact of pulmonary hypertension in patients with severe aortic stenosis undergoing valve replacement","volume":"21","author":"Weber","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0146","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ejhf.864","article-title":"Implication of pulmonary hypertension in patients undergoing MitraClip therapy: results from the German transcatheter mitral valve interventions (TRAMI) registry","volume":"20","author":"Tigges","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0147","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115024566600_ehf213124-bib-0148","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"2026012115024566600_ehf213124-bib-0149","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1234","article-title":"Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"20","author":"Komajda","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0150","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012115024566600_ehf213124-bib-0151","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ejhf.1159","article-title":"The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease\u2013existing evidence, knowledge gaps, and future directions","volume":"20","author":"Ambrosy","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0152","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ejhf.1139","article-title":"Effect of sacubitril\/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)","volume":"20","author":"Mogensen","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0153","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ejhf.1402","article-title":"Reduced loop diuretic use in patients taking sacubitril\/valsartan compared with enalapril: the PARADIGM-HF trial","volume":"21","author":"Vardeny","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0154","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0155","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ejhf.1670","article-title":"Initiation of sacubitril\/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study","volume":"22","author":"Senni","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0156","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/ejhf.1532","article-title":"Sacubitril\/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency\/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world","volume":"21","author":"Kapelios","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0157","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ejhf.1465","article-title":"Real-world treatment patterns of sacubitril\/valsartan: a longitudinal cohort study in Germany","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0158","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ejhf.1459","article-title":"Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry","volume":"21","author":"Komajda","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0159","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/ejhf.887","article-title":"Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry","volume":"19","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0160","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ehf2.12258","article-title":"Insights into implementation of sacubitril\/valsartan into clinical practice","volume":"5","author":"Martens","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0161","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ejhf.1645","article-title":"Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry","volume":"22","author":"Lain\u0161\u010dak","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0162","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0163","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ejhf.1054","article-title":"Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril\/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study","volume":"20","author":"Senni","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0164","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ejhf.1400","article-title":"Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial","volume":"21","author":"Ferreira","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0165","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/ejhf.1217","article-title":"Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists","volume":"20","author":"Butler","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0166","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/ejhf.1079","article-title":"Potassium and the use of renin\u2013angiotensin\u2013aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF","volume":"20","author":"Beusekamp","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0167","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"Trevisan","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0168","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1093\/eurheartj\/ehv565","article-title":"Improving outcomes in heart failure: a personal perspective","volume":"36","author":"McMurray","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012115024566600_ehf213124-bib-0169","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovi\u0107","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0170","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ejhf.1673","article-title":"European Society of Cardiology\/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure","volume":"22","author":"Seferovi\u0107","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0171","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/ejhf.1663","article-title":"Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial","volume":"22","author":"B\u00f6hm","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0172","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012115024566600_ehf213124-bib-0173","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium\u2013glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0174","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/ejhf.1548","article-title":"The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0175","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012115024566600_ehf213124-bib-0176","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ejhf.1536","article-title":"Evaluation of the effect of sodium\u2013glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial","volume":"21","author":"Packer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0177","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","author":"Bhatt","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012115024566600_ehf213124-bib-0178","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ejhf.1596","article-title":"Evaluation of the effects of sodium\u2013glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0179","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/ejhf.1486","article-title":"Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure","volume":"21","author":"Abraham","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0180","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/ejhf.1185","article-title":"Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure","volume":"20","author":"Packer","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0181","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ehf2.12505","article-title":"The effects of sodium\u2013glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions","volume":"6","author":"Lan","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0182","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/ejhf.1328","article-title":"Empagliflozin directly improves diastolic function in human heart failure","volume":"20","author":"Pabel","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0183","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","article-title":"Sodium\u2013glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction","volume":"21","author":"Yurista","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0184","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ehf2.12333","article-title":"Iron deficiency in chronic heart failure: case-based practical guidance","volume":"5","author":"Lam","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0185","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ejhf.938","article-title":"Limited contractile reserve contributes to poor peak exercise capacity in iron-deficient heart failure","volume":"20","author":"Martens","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0186","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ejhf.1154","article-title":"Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function","volume":"20","author":"Hoes","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0187","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"2026012115024566600_ehf213124-bib-0188","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012115024566600_ehf213124-bib-0189","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/jcsm.12314","article-title":"Iron deficiency as energetic insult to skeletal muscle in chronic diseases","volume":"9","author":"Dziegala","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026012115024566600_ehf213124-bib-0190","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/jcsm.12282","article-title":"Depleted iron stores are associated with inspiratory muscle weakness independently of skeletal muscle mass in men with systolic chronic heart failure","volume":"9","author":"Tkaczyszyn","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026012115024566600_ehf213124-bib-0191","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/jcsm.12283","article-title":"hmSOD1 gene mutation-induced disturbance in iron metabolism is mediated by impairment of Akt signalling pathway","volume":"9","author":"Halon-Golabek","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026012115024566600_ehf213124-bib-0192","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/ehf2.12581","article-title":"The chameleon of cardiology: cardiac sarcoidosis before and after heart transplantation","volume":"7","author":"Sedaghat-Hamedani","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0193","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/ejhf.1305","article-title":"Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice","volume":"20","author":"McDonagh","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0194","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ejhf.823","article-title":"Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis","volume":"20","author":"Anker","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0195","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/ejhf.1710","article-title":"Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure","volume":"21","author":"Ponikowski","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0196","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"2026012115024566600_ehf213124-bib-0197","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012115024566600_ehf213124-bib-0198","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/ejhf.1664","article-title":"Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial","volume":"21","author":"Pieske","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0199","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","author":"Teerlink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012115024566600_ehf213124-bib-0200","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/ejhf.1591","article-title":"Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial","volume":"21","author":"Voors","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0201","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/ejhf.1557","article-title":"Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials","volume":"21","author":"Ahmad","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0202","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ejhf.1145","article-title":"Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial","volume":"20","author":"Com\u00edn-Colet","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0203","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/ejhf.1452","article-title":"Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study","volume":"21","author":"Bavendiek","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0204","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ejhf.929","article-title":"Effect of expanding evidence and evolving clinical guidelines on the prevalence of indication for cardiac resynchronization therapy in patients with heart failure","volume":"20","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0205","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/ejhf.1142","article-title":"CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients\u2013who is doing what to whom and how?","volume":"20","author":"Dickstein","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0206","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehx137","article-title":"Cardiac resynchronization therapy in the real world: need to focus on implant rates, patient selection, co-morbidities, type of devices, and complications","volume":"38","author":"Boriani","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012115024566600_ehf213124-bib-0207","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.hrthm.2012.04.026","article-title":"Cardiac resynchronization therapy (CRT): clinical trials, guidelines, and target populations","volume":"9","author":"Linde","year":"2012","journal-title":"Heart Rhythm"},{"key":"2026012115024566600_ehf213124-bib-0208","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ejhf.1133","article-title":"The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis","volume":"20","author":"Linde","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0209","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ejhf.1552","article-title":"Body mass index and outcomes of cardiac resynchronization with implantable cardioverter-defibrillator therapy in older patients with heart failure","volume":"21","author":"Echouffo-Tcheugui","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0210","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/ejhf.1235","article-title":"Upgrades from a previous device compared to de novo cardiac resynchronization therapy in the European Society of Cardiology CRT Survey II","volume":"20","author":"Linde","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0211","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ejhf.1427","article-title":"Clinical features, predictors, and long-term prognosis of pacing-induced cardiomyopathy","volume":"21","author":"Cho","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0212","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ejhf.1117","article-title":"Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations","volume":"20","author":"Gasparini","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0213","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/ejhf.1392","article-title":"Irregular pacing of ventricular cardiomyocytes induces pro-fibrotic signalling involving paracrine effects of transforming growth factor beta and connective tissue growth factor","volume":"21","author":"Slawik","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0214","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ehf2.12407","article-title":"Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial","volume":"6","author":"Lee","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0215","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N Engl J Med"},{"key":"2026012115024566600_ehf213124-bib-0216","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/ejhf.1192","article-title":"Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes","volume":"20","author":"Sharma","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0217","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ehf2.12287","article-title":"Mitral valve interventions in heart failure","volume":"5","author":"Lavall","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0218","doi-asserted-by":"crossref","first-page":"JC7","DOI":"10.7326\/ACPJC-2019-170-2-007","article-title":"In HF with secondary mitral regurgitation, transcatheter mitral valve repair reduced HF hospitalizations at 2 years","volume":"170","author":"Donato","year":"2019","journal-title":"Ann Intern Med"},{"key":"2026012115024566600_ehf213124-bib-0219","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/ejhf.1616","article-title":"Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2\u2009years","volume":"21","author":"Iung","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0220","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/ejhf.1491","article-title":"Treatment of functional mitral regurgitation in chronic heart failure: can we get a \u2018proof of concept\u2019 from the MITRA-FR and COAPT trials?","volume":"21","author":"Senni","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0221","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ejhf.910","article-title":"Safety and efficacy of MitraClip\u2122 therapy in patients with severely impaired left ventricular ejection fraction: results from the German transcatheter mitral valve interventions (TRAMI) registry","volume":"20","author":"Geis","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0222","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ejhf.1147","article-title":"Six-month outcome after transcatheter edge-to-edge repair of severe tricuspid regurgitation in patients with heart failure","volume":"20","author":"Orban","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0223","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/ejhf.1547","article-title":"Aetiology-based clinical scenarios predict outcomes of transcatheter edge-to-edge tricuspid valve repair of functional tricuspid regurgitation","volume":"21","author":"Schlotter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0224","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/ejhf.779","article-title":"Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes","volume":"19","author":"Gustafsson","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0225","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa1602954","article-title":"Intrapericardial left ventricular assist device for advanced heart failure","volume":"376","author":"Rogers","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012115024566600_ehf213124-bib-0226","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.jacc.2017.02.018","article-title":"Left ventricular assist device as a bridge to recovery for patients with advanced heart failure","volume":"69","author":"Jakovljevic","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026012115024566600_ehf213124-bib-0227","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ejhf.956","article-title":"Clinical outcomes of temporary mechanical circulatory support as a direct bridge to heart transplantation: a nationwide Spanish registry","volume":"20","author":"Barge-Caballero","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0228","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ejhf.1018","article-title":"Clinical and histopathological effects of heart failure drug therapy in advanced heart failure patients on chronic mechanical circulatory support","volume":"20","author":"Catino","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0229","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ejhf.1568","article-title":"Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry","volume":"21","author":"Cikes","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0230","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/ejhf.1431","article-title":"Exercise training in patients with a left ventricular assist device (Ex-VAD): rationale and design of a multicentre, prospective, assessor-blinded, randomized, controlled trial","volume":"21","author":"Bobenko","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0231","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/ejhf.975","article-title":"Screening for heart transplantation and left ventricular assist system: results from the ScrEEning for advanced Heart Failure treatment (SEE-HF) study","volume":"20","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0232","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ejhf.1113","article-title":"Platelet activation is a preoperative risk factor for the development of thromboembolic complications in patients with continuous-flow left ventricular assist device","volume":"20","author":"Consolo","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0233","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ejhf.1284","article-title":"Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure\u2013two-year results from the HeartMate 3\u2009CE Mark Study","volume":"21","author":"Schmitto","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0234","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/ejhf.1300","article-title":"Telemedical Interventional Management in Heart Failure II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: study design and description of the intervention","volume":"20","author":"Koehler","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0235","article-title":"Telemonitoring in patients with chronic heart failure and moderate depressed symptoms\u2013results of the Telemedical Interventional Monitoring in Heart Failure (TIM-HF) study","author":"Koehler","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0236","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12471-018-1202-5","article-title":"Telemedicine in heart failure\u2013more than nice to have?","volume":"27","author":"Eurlings","year":"2019","journal-title":"Neth Heart J"},{"key":"2026012115024566600_ehf213124-bib-0237","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/ejhf.1053","article-title":"Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study","volume":"20","author":"McDonald","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0238","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ejhf.1354","article-title":"Effectiveness of the European Society of Cardiology\/Heart Failure Association website \u2018heartfailurematters.org\u2019 and an e-health adjusted care pathway in patients with stable heart failure: results of the \u2018e-Vita HF\u2019 randomized controlled trial","volume":"21","author":"Wagenaar","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0239","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ejhf.1386","article-title":"E-health in self-care of heart failure patients: promises become reality","volume":"21","author":"Piepoli","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0240","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ejhf.1351","article-title":"Medication dosing for heart failure with reduced ejection fraction\u2013opportunities and challenges","volume":"21","author":"Marti","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0241","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ejhf.1503","article-title":"Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial","volume":"21","author":"Schulz","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0242","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/ejhf.1669","article-title":"Less invasive ventricular reconstruction for ischaemic heart failure","volume":"21","author":"Klein","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0243","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/ejhf.1700","article-title":"Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the MSC-HF trial","volume":"22","author":"Mathiasen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0244","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ejhf.1412","article-title":"Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE)","volume":"21","author":"Paitazoglou","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0245","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ejhf.1349","article-title":"Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond","volume":"21","author":"Tsch\u00f6pe","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0246","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/ejhf.1048","article-title":"Adaptive servo-ventilation for central sleep apnoea in systolic heart failure: results of the major substudy of SERVE-HF","volume":"20","author":"Cowie","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0247","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/ejhf.1312","article-title":"Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure","volume":"20","author":"Costanzo","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0248","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ejhf.1672","article-title":"Changes in m6A RNA methylation contribute to heart failure progression by modulating translation","volume":"22","author":"Berulava","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0249","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/ejhf.1608","article-title":"Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets","volume":"22","author":"Cao","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0250","article-title":"The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach","author":"Hoes","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0251","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/ehf2.12418","article-title":"Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan","volume":"6","author":"Shiga","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0252","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","article-title":"Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease","volume":"7","author":"Beldhuis","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0253","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jchf.2018.05.018","article-title":"The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF","volume":"6","author":"Savji","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0254","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ejhf.1621","article-title":"Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis","volume":"22","author":"Segar","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0255","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/ejhf.1593","article-title":"Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial","volume":"22","author":"Ramalho","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0256","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/ejhf.1671","article-title":"Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction","volume":"22","author":"Yang","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0257","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/ejhf.1188","article-title":"Adiposity, body composition and ventricular-arterial stiffness in the elderly: the Atherosclerosis Risk in Communities Study","volume":"20","author":"Fernandes-Silva","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0258","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ejhf.1646","article-title":"Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0259","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ejhf.1335","article-title":"Heart failure with preserved ejection fraction in Asia: the far side of the moon?","volume":"21","author":"Senni","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0260","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"2026012115024566600_ehf213124-bib-0261","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"2026012115024566600_ehf213124-bib-0262","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ejhf.1614","article-title":"Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction","volume":"22","author":"Barandiar\u00e1n Aizpurua","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0263","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ejhf.976","article-title":"Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction","volume":"20","author":"Wolsk","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0264","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ejhf.979","article-title":"Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Corr\u00e0","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0265","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/ejhf.913","article-title":"Physiological dead space and arterial carbon dioxide contributions to exercise ventilatory inefficiency in patients with reduced or preserved ejection fraction heart failure","volume":"19","author":"Van Iterson","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0266","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/ejhf.1140","article-title":"A flattening oxygen consumption trajectory phenotypes disease severity and poor prognosis in patients with heart failure with reduced, mid-range, and preserved ejection fraction","volume":"20","author":"Popovic","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0267","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/ejhf.1407","article-title":"Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT","volume":"21","author":"Grodin","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0268","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012115024566600_ehf213124-bib-0269","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/ejhf.1194","article-title":"Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial","volume":"20","author":"Ravassa","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0270","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ejhf.1535","article-title":"Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction","volume":"21","author":"Shen","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0271","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ejhf.960","article-title":"Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial)","volume":"20","author":"Trippel","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0272","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/ejhf.1619","article-title":"Long-term effects of Na+\/Ca2+ exchanger inhibition with ORM-11035 improves cardiac function and remodelling without lowering blood pressure in a model of heart failure with preserved ejection fraction","volume":"21","author":"Primessnig","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0273","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ejhf.901","article-title":"Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality","volume":"20","author":"Platz","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0274","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ejhf.1323","article-title":"Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study","volume":"21","author":"Ferreira","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0275","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ejhf.1341","article-title":"Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care","volume":"21","author":"Greene","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0276","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ejhf.1630","article-title":"Assessing the evidence-practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics","volume":"22","author":"Li","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0277","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ejhf.1078","article-title":"Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF","volume":"20","author":"Pokorney","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0278","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1002\/ehf2.12847","article-title":"In-hospital and long-term mortality for acute heart failure: analysis at the time of admission to the emergency department","volume":"7","author":"Lombardi","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0279","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/ejhf.1567","article-title":"Departments involved during the first episode of acute heart failure and subsequent emergency department revisits and rehospitalisations: an outlook through the NOVICA cohort","volume":"21","author":"Mir\u00f3","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0280","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/ejhf.1204","article-title":"Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"20","author":"Harjola","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0281","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/ejhf.1492","article-title":"Acute heart failure congestion and perfusion status\u2013impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry","volume":"21","author":"Chioncel","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0282","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ejhf.1502","article-title":"Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes","volume":"21","author":"Javaloyes","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0283","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/ejhf.1050","article-title":"Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion","volume":"20","author":"van Aelst","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0284","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/ejhf.1533","article-title":"Controlled decongestion by Reprieve therapy in acute heart failure: results of the TARGET-1 and TARGET-2 studies","volume":"21","author":"Biegus","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0285","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/ejhf.1428","article-title":"Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure","volume":"21","author":"Biegus","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0286","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/ejhf.1627","article-title":"B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure","volume":"21","author":"Wettersten","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0287","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/ejhf.1383","article-title":"Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure","volume":"21","author":"Pellicori","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0288","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ejhf.1437","article-title":"Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure","volume":"21","author":"ter Maaten","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0289","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/ejhf.1660","article-title":"Mid-regional pro-adrenomedullin outperforms N-terminal pro-B-type natriuretic peptide for the diagnosis of acute heart failure in the presence of atrial fibrillation","volume":"22","author":"Kuan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0290","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ejhf.1693","article-title":"Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission","volume":"22","author":"Pandhi","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0291","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/ejhf.1156","article-title":"Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion","volume":"20","author":"Zymli\u0144ski","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0292","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/ejhf.1378","article-title":"Multi-organ dysfunction\/injury on admission identifies acute heart failure patients at high risk of poor outcome","volume":"21","author":"Zymli\u0144ski","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0293","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ejhf.1642","article-title":"Short-term prognostic implications of serum and urine neutrophil gelatinase-associated lipocalin in acute heart failure: findings from the AKINESIS study","volume":"22","author":"Wettersten","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0294","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ejhf.1592","article-title":"Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial","volume":"21","author":"Blumer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0295","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ejhf.1379","article-title":"Lung ultrasound integrated with clinical assessment for the diagnosis of acute decompensated heart failure in the emergency department: a randomized controlled trial","volume":"21","author":"Pivetta","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0296","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ejhf.1678","article-title":"Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"\u010celutkien\u0117","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0297","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/ejhf.1414","article-title":"Lung ultrasound for the diagnosis of acute heart failure: time to upgrade current indication?","volume":"21","author":"Bistola","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0298","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/ejhf.839","article-title":"Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review","volume":"19","author":"Platz","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0299","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/ejhf.1604","article-title":"Lung ultrasound-guided treatment in ambulatory patients with heart failure: a randomized controlled clinical trial (LUS-HF study)","volume":"21","author":"Rivas-Lasarte","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0300","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/ejhf.1499","article-title":"Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure","volume":"21","author":"Platz","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0301","doi-asserted-by":"crossref","DOI":"10.1016\/j.pcad.2020.04.007","article-title":"Acute heart failure: more questions than answers","author":"Tomasoni","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"2026012115024566600_ehf213124-bib-0302","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion\u2013a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0303","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ejhf.1478","article-title":"Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance","volume":"21","author":"Verbrugge","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0304","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/ejhf.1307","article-title":"Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial","volume":"20","author":"Mullens","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0305","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ejhf.889","article-title":"Systolic blood pressure reduction during the first 24\u2009h in acute heart failure admission: friend or foe?","volume":"20","author":"Cotter","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0306","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJMoa1801291","article-title":"Effects of serelaxin in patients with acute heart failure","volume":"381","author":"Metra","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012115024566600_ehf213124-bib-0307","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ejhf.1692","article-title":"Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis","volume":"22","author":"Teerlink","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0308","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ejhf.1368","article-title":"Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU","volume":"21","author":"Maggioni","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0309","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/ejhf.1504","article-title":"Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure","volume":"21","author":"Felker","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0310","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ejhf.932","article-title":"Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study","volume":"20","author":"Gayat","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115024566600_ehf213124-bib-0311","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/ejhf.1575","article-title":"Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study","volume":"21","author":"Kimmoun","year":"2019","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13124","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/6\/3505\/65902343\/eschf_7_6_3505.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/6\/3505\/65902343\/eschf_7_6_3505.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:03:34Z","timestamp":1769025814000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/7\/6\/3505\/8372473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":311,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,12,5]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13124","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"2020-11-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}